Context: The extent of the glycemic variability in diabetes secondary to total pancreatectomy is not fully understood.
Objective: To evaluate glycemic variability in totally pancreatectomized (PX) patients and compare it to glycemic variability in hemoglobin A1c (HbA1c)-matched patients with long-standing type 1 diabetes (T1D).
Design: A case-control study was performed.
Aims/hypothesis: Treatment of diabetes secondary to total pancreatectomy remains a challenge and insulin constitutes the only glucose-lowering treatment for these patients. We hypothesised that the glucagon-like peptide 1 (GLP-1) receptor agonist lixisenatide would improve postprandial glucose tolerance in totally pancreatectomised patients.
Methods: In a double-blinded, randomised, crossover study, 12 totally pancreatectomised individuals (age: 65.